Inhibitory Effect of Sub-conjunctival Tocilizumab on Alkali Burn Induced Corneal Neovascularization in Rats

REFERENCES

• Hoffart L, Matonti F, Conrath J, Daniel L, Ridings B, Masson GS, et al. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol 2010;38:346–352
   PubMed Web of Science ®Google Scholar
• Chévez-Barrios P. Are we getting closer to prevention and treatment of corneal neovascularization? Clin Experiment Ophthalmol 2007;35:689–690
   Google Scholar
• Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242–249
   PubMed Web of Science ®Google Scholar
• Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand 2006;84:282–288
   PubMedGoogle Scholar
• Ozdemir O, Altintas O, Altintas L, Yildiz DK, Sener E, Caglar Y. Effects of sub-conjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization. Can J Ophthalmol 2013;48:115–120
   PubMed Web of Science ®Google Scholar
• Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983;101:640–643
   PubMed Web of Science ®Google Scholar
• Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992;110:405–407
   PubMed Web of Science ®Google Scholar
• Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007;105:330–343
   PubMedGoogle Scholar
• Li C, Li L, Cheng R, Dai Z, Li C, Yao Y, Zhou T, et al. Acidic/neutral amino acid residues substitution in NH2 terminal of plasminogen kringle 5 exerts enhanced effects on corneal neovascularization. Cornea 2013;32:680–688
   Google Scholar
• Jovanovic V, Nikolic L. The effect of topical doxycycline on corneal neovascularization. Curr Eye Res 2014;39:142--148
   PubMed Web of Science ®Google Scholar
• Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 2012;5:415–429
   Google Scholar
• Sakimoto T, Sugaya S, Ishimori, Sawa M. Anti-inflammatory effect of IL-6 receptor blockade in corneal alkali burn. Exp Eye Res 2012;97:98–104
   PubMed Web of Science ®Google Scholar
• Okuda Y, Ohnishi M, Matoba K. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 2014;24:137–143
   PubMed Web of Science ®Google Scholar
• Shinkura H, Imazeki I, Fukushima N, Chiba N, Takahashi F, Aikawa H, et al. Safety and kinetic properties of a humanized antibody to human interleukin-6 receptor in healthy non-human primates. Toxicology. 1997;122:163–170
   Google Scholar
• Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012;8:1227–1236
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 2014;252:163--164
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernandez MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632
   PubMed Web of Science ®Google Scholar
• Nishida T, Nakamura M, Mishima H, Otori T. Interleukin 6 facilitates corneal epithelial wound closure in vivo. Arch Ophthalmol 1992;110:1292–1294
   PubMed Web of Science ®Google Scholar
• Ozdemir O, Altıntas O, Altıntas L, Yıldız DK, Sener E, Yuksel N. The comparison of efficacy of topical bevacizumab, etanercept and the combination of both drugs on experimental corneal neovascularization. Turkiye Klinikleri J Ophthalmol 2012;21:211–219
   Google Scholar
• Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1–78
   PubMed Web of Science ®Google Scholar
• Ebrahem Q, Minamoto A, Hoppe G, Anan-Apte B, Sears JE. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci 2006;47:4935–4941
   PubMed Web of Science ®Google Scholar
• Wu PC, Yang LC, Kuo HK. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis. 2005:13;11:28–35
   Google Scholar
• Türkcü FM, Cinar Y, Türkcü G, Sahin A, Cingu AK, Yüksel H, et al. Topical and sub-conjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model. Cutan Ocul Toxicol. 2013 Jul 17. [Epub ahead of print]
   Google Scholar
• Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804–807
   PubMed Web of Science ®Google Scholar
• Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514–2522
   PubMed Web of Science ®Google Scholar
• Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemır O, Caglar Y, et al. The impact of sub-conjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 2011;36:1005–1013
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95–113
   PubMed Web of Science ®Google Scholar
• Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by sub-conjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424–431
   PubMedGoogle Scholar
• Güler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009;147:703–708
   PubMed Web of Science ®Google Scholar
• Wiejak J, Dunlop J, Mackay SP, Yarwood SJ. Flavanoids induce expression of the suppressor of cytokine signalling 3 (SOCS3) gene and suppress IL-6-activated signal transducer and activator of transcription 3 (STAT3) activation in vascular endothelial cells. Biochem J 2013;454:283–293
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000–2008
   PubMed Web of Science ®Google Scholar
• Rocher N, Behar-Cohen F, Pournaras JA, Naud MC, Jeanny JC, Jonet L, et al. Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and sub-conjunctival routes. Mol Vis 2011;17:104–112
   PubMed Web of Science ®Google Scholar
• Ahmed A, Berati H, Nalan A, Aylin S. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Experiment Ophthalmol. 2009;37:730–736
   PubMed Web of Science ®Google Scholar
• Terayama N, Terada T, Nakanuma Y. A morphometric and immunohistochemical study on angiogenesis of human metastatic carcinomas of the liver. Hepatology 1996;24:816–819
   PubMed Web of Science ®Google Scholar